Skip to Content
Morningstar
Get 14 Days Free

Illumina Inc ILMN

Morningstar Rating
Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Illumina Closes Grail Acquisition Despite Pending EU and U.S. Regulatory Reviews; No FVE Change

Julie Utterback, CFA Senior Equity Analyst

Analyst Note

| Julie Utterback, CFA |

Narrow-moat Illumina announced that it completed the acquisition of liquid biopsy test maker Grail, despite ongoing reviews of the transaction by European Union and U.S. regulators. Our fair value estimate already includes the acquisition of Grail starting in 2022, so moving up the completion date by a few months should not materially alter our view, although we may tinker with our estimates a bit. However, the decision to acquire Grail prior to getting clearance from key regulatory agencies is highly unusual and could expose Illumina to additional risks, although the Grail opportunity appears so great that management has determined they are worth it.

Read Full Analysis

Company Profile

Business Description

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates revenue from sequencing tools and dedicated consumables (76% of 2020 sales). Illumina’s high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications. Services account for 16% of sales and include basic maintenance services, clinical lab applications (such as noninvasive prenatal, oncology, and rare-disease screening), and whole genome sequencing.

Contact
200 Illumina Way
San Diego, CA, 92122
T +1 858 202-4500
Sector Healthcare
Industry Diagnostics & Research
Most Recent Earnings Jun 30, 2021
Fiscal Year End Dec 30, 2020
Stock Type Slow Growth
Employees 7,850

Related

Market Update
The Winners of the New Definition of Infrastructure
Depending on which broader infrastructure projects take shape, numerous companies could see increased demand.
David Sekera
Our Picks
9 Wide-Moat Stocks of Tomorrow
These narrow-moat firms have positive moat trends and are run by exemplary stewards of capital.
Susan Dziubinski
Stock Strategist Industry Reports
A New Frontier in Cancer Screening and Treatment
If liquid biopsy lives up to its potential, a paradigm shift in cancer detection is possible.
Julie Utterback
US Videos
3 Promising Stocks in Early Cancer Detection
We see opportunities in the liquid biopsy market.
Morningstar
ETF Specialist
A Risky, But Promising, Innovation ETF
This actively managed ETF offers a thoughtful approach to investing in innovative companies, but it's not for the faint-of-heart.
Alex Bryan
Premium Article
More Stocks for the Next Decade
Given their ties with promising technologies, these companies stand to benefit in the 2020s.
Susan Dziubinski
Our Picks
3 Stocks for the Next Decade
We think these companies are poised to experience meaningful economic benefits in the future.
Susan Dziubinski
Premium Article
7 Wide-Moat Stocks of Tomorrow
These narrow-moat firms have positive moat trends and are run by exemplary stewards of capital.
Susan Dziubinski
Commentary
How International Is Your Foreign-Stock Fund?
Revenue by region highlights hidden U.S. and emerging-markets exposures in foreign stock funds.
Gabrielle Dibenedetto
Fund Times
2 Top Managers on Secular Change and the Market
T. Rowe Price's David Giroux and Wellington Management's Jean Hynes talk value investing, innovation in healthcare, and where they're finding opportunity.
Susan Dziubinski
Fund Spy
The Year in U.S. Equity Funds: Growth Was King in 2017
Tech-heavy large-growth funds fared best while small-value funds posted smaller gains.
David Kathman
Fund Spy
First Quarter in U.S. Equity Funds: Growth Dominates Value
After a tough 2016, growth made a comeback in 2017's first quarter.
Andrew Daniels
US Videos
Weekly Wrap: What's Next for Chipotle
The fast-casual chain is moving on after a food safety scare, but we think it could be an up and down year for the firm. Plus, positive reaction for Illumina, and we're bearish on steel.
Jeremy Glaser
Stock Analyst Update
Illumina Should Dominate in High-Throughput Sequencing
The narrow moat company's results and announcements give us confidence in its ability to drive innovation in the genome sequencing market and maintain its competitive advantage.
Michael Waterhouse
Market Update
Is There Opportunity in Personalized Medicine?
Although we're in the early innings of the personal-medication revolution, the stock prices of most biotech companies are sky-high.
John Waggoner
Stock Strategist
Leader in Genomic Sequencing Illuminates the Way
Continued technology advancements and market expansion support Illumina's narrow moat.
Michael Waterhouse
Stock Strategist
A Shift in Health-Care M&A Activity
Recent deals have been driven more by tax strategies than therapeutic synergies.
Basili Alukos
Quarter-End Insights
Credit Outlook: Sector Updates and Top Bond Picks
Get our sector-by-sector take on the bond market, plus our five best bond ideas.
David Sekera
Quarter-End Insights
Our Outlook for Health-Care Stocks
Election and potential sequestration emerge as key topics for health care.
Alex Morozov
US Videos
Glasses Half Full
Morningstar markets editor Jeremy Glaser examines the optimistic angle on manufacturing, Apple, J.C. Penney, AT&T, and more.
Jason Stipp

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.